We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing
News

Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing

Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing
News

Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nanogen, Inc. has announced that it has signed an end user license agreement (EULA) with Quest Diagnostics for use of the Company’s proprietary MGB Probe technology in human in vitro diagnostic testing.

Under the licensing agreement, Quest Diagnostics will have rights to use and sell products and services incorporating the MGB Probe technology. Terms of the EULA include an upfront fee and royalties paid on tests sold using the licensed technology.

“We’re proud that Quest Diagnostics, the world’s leader in diagnostic testing, is using our proprietary minor groove binder (MGB) technology and incorporating it into some of their laboratory developed molecular tests,” said Merl Hoekstra, Nanogen’s Vice President of Corporate and Business Development. “We’re proud of the growing reputation and the expanding base of licensed end users of our technology.”

The Company’s MGB Probe technology is broadly licensed in the research and clinical fields and accounts for a majority of the Company’s revenue today. Nanogen has more than 40 reagent and kit products sold for in vitro diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.
Advertisement